JP2009533465A5 - - Google Patents

Download PDF

Info

Publication number
JP2009533465A5
JP2009533465A5 JP2009505564A JP2009505564A JP2009533465A5 JP 2009533465 A5 JP2009533465 A5 JP 2009533465A5 JP 2009505564 A JP2009505564 A JP 2009505564A JP 2009505564 A JP2009505564 A JP 2009505564A JP 2009533465 A5 JP2009533465 A5 JP 2009533465A5
Authority
JP
Japan
Prior art keywords
polypeptide
dvl
item
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009505564A
Other languages
English (en)
Japanese (ja)
Other versions
JP5290148B2 (ja
JP2009533465A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/066267 external-priority patent/WO2007121147A2/en
Publication of JP2009533465A publication Critical patent/JP2009533465A/ja
Publication of JP2009533465A5 publication Critical patent/JP2009533465A5/ja
Application granted granted Critical
Publication of JP5290148B2 publication Critical patent/JP5290148B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009505564A 2006-04-10 2007-04-09 Disheveled(Dvl)PDZ修飾因子 Expired - Fee Related JP5290148B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79067306P 2006-04-10 2006-04-10
US60/790,673 2006-04-10
PCT/US2007/066267 WO2007121147A2 (en) 2006-04-10 2007-04-09 Disheveled pdz modulators

Publications (3)

Publication Number Publication Date
JP2009533465A JP2009533465A (ja) 2009-09-17
JP2009533465A5 true JP2009533465A5 (cg-RX-API-DMAC7.html) 2010-05-20
JP5290148B2 JP5290148B2 (ja) 2013-09-18

Family

ID=38537937

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009505564A Expired - Fee Related JP5290148B2 (ja) 2006-04-10 2007-04-09 Disheveled(Dvl)PDZ修飾因子

Country Status (8)

Country Link
US (2) US7695928B2 (cg-RX-API-DMAC7.html)
EP (2) EP2343551B1 (cg-RX-API-DMAC7.html)
JP (1) JP5290148B2 (cg-RX-API-DMAC7.html)
CN (2) CN101467039B (cg-RX-API-DMAC7.html)
AU (1) AU2007238186B2 (cg-RX-API-DMAC7.html)
CA (1) CA2648322C (cg-RX-API-DMAC7.html)
ES (2) ES2385261T3 (cg-RX-API-DMAC7.html)
WO (1) WO2007121147A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI596109B (zh) * 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
KR101278073B1 (ko) * 2008-08-04 2013-06-24 연세대학교 산학협력단 Idbf의 신규 용도
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
MX366804B (es) 2012-02-11 2019-07-25 Genentech Inc Translocaciones de la r-espondina y sus metodos de uso.
GB201220891D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating breast cancers
GB201220901D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating pancreatic cancer
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Kntc2胜肽及含此胜肽之疫苗
US9520180B1 (en) 2014-03-11 2016-12-13 Hypres, Inc. System and method for cryogenic hybrid technology computing and memory
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8319174D0 (en) * 1983-07-15 1983-08-17 Erba Farmitalia Biologically active heptapeptides
GB8430255D0 (en) * 1984-11-30 1985-01-09 Erba Farmitalia Biologically active oligopeptides
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
CA2345497A1 (en) 1988-10-28 1990-04-28 Genentech, Inc. Growth hormone variants and method for forming growth hormone variants
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5688936A (en) * 1992-06-11 1997-11-18 The Regents Of The University Of California Vesicle membrane transport proteins
DK0674506T3 (da) 1992-12-02 2001-01-08 Alkermes Inc Væksthormonholdige mikrosfærer med styret frigivelse
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
DK0779806T3 (da) 1994-09-09 2000-11-27 Takeda Chemical Industries Ltd Præparat til forsinket frigivelse indeholdende et metalsalt af et peptid
CN1102854C (zh) 1995-06-07 2003-03-12 阿尔克姆斯控制治疗公司 人生长激素的延续释放组合物
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6294330B1 (en) 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
JP2002522029A (ja) 1998-07-27 2002-07-23 ジェネンテック・インコーポレーテッド コートタンパク質の改変によるファージ提示における改良した形質転換効率
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
WO2002090544A2 (en) 2001-05-04 2002-11-14 Hybrigenics Protein-protein interactions in adipocyte cells (3)
JP2004533840A (ja) * 2001-07-06 2004-11-11 ジェネンテック・インコーポレーテッド ファージディスプレイによるpdzドメインリガンド
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
CA2501235A1 (en) 2002-10-04 2004-04-22 The Regents Of The University Of California Methods for treating cancer by inhibiting wnt signaling
CA2572469A1 (en) * 2004-07-01 2006-01-19 The Regents Of The University Of California Small molecule inhibition of a pdz-domain interaction

Similar Documents

Publication Publication Date Title
JP2009533465A5 (cg-RX-API-DMAC7.html)
Adihou et al. A protein tertiary structure mimetic modulator of the Hippo signalling pathway
Chevet et al. Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development
AU784845B2 (en) Cell-permeable peptide inhibitors of the JNK signal transduction pathway
Jenssen et al. Serum stability of peptides
Loerch et al. Unmasking the U2AF homology motif family: a bona fide protein–protein interaction motif in disguise
EA200800536A1 (ru) Тканезащитные пептиды и их применения
Li et al. ATAD3, a vital membrane bound mitochondrial ATPase involved in tumor progression
US20120142613A1 (en) Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
Hoshijima et al. Roles of heterotypic CCN2/CTGF–CCN3/NOV and homotypic CCN2–CCN2 interactions in expression of the differentiated phenotype of chondrocytes
JP2014510518A5 (cg-RX-API-DMAC7.html)
JP2010522541A5 (cg-RX-API-DMAC7.html)
AU2025204787A1 (en) COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS
JP2010528584A5 (cg-RX-API-DMAC7.html)
CN116801908A (zh) 用于降解病毒和宿主蛋白的嵌合缀合物和使用方法
CA2357015A1 (en) Agents for treating human illnesses based on .beta.-catenin, and the production and use thereof
EP2268658A1 (en) Peptides and aptamers thereof as specific modulators of mutant p53 function
Altieri et al. Anti-amyloidogenic property of human gastrokine 1
DE69819505D1 (de) Mit smad wechselwirkende polypeptide und verwendungen davon
Johansson et al. Tetrapeptides as potent protease inhibitors of hepatitis C virus full-length NS3 (protease-helicase/NTPase)
Denholt et al. Identification of novel peptide ligands for the cancer‐specific receptor mutation EFGRvIII using a mixture‐based synthetic combinatorial library
JP2012512259A (ja) クプレドキシンにより癌を予防するための組成物および方法
Puszko et al. Urea moiety as amide bond mimetic in peptide-like inhibitors of VEGF-A165/NRP-1 complex
Katritzky et al. Microwave‐assisted solid‐phase peptide synthesis utilizing N‐Fmoc‐protected (α‐aminoacyl) benzotriazoles
DE69925116D1 (de) Neue, physiologisch aktive peptide und ihre verwendung.